Dudediligence.

Tarsus Pharmaceuticals, Inc

TARSNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$48.1MSep ’24$66.4MDec ’24$78.3MMar ’25$102.7MJun ’25$118.7MSep ’25$151.7MDec ’25$162.1MMar ’26$173.9MJun ’26
Net income, by quarter
−$23.4MSep ’24−$23.1MDec ’24−$25.1MMar ’25−$20.3MJun ’25−$12.6MSep ’25−$8.0MDec ’25−$7.0MMar ’26−$18.6MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$57.0M$25.8M$17.4M$183.0M$451.4M
Operating income−$12.2M−$62.7M−$143.2M−$120.6M−$71.0M
Net income−$13.8M−$62.1M−$135.9M−$115.6M−$66.0M
Operating cash flow$3.7M−$49.0M−$117.5M−$83.0M−$12.5M
Free cash flow$3.2M−$49.5M−$119.0M−$84.6M−$22.3M
Cash$171.3M$71.7M$224.9M$97.4M$183.6M
Debt$0.00$19.4M$29.8M$71.8M$72.4M
Shares outstanding20.7M26.7M34.2M38.3M42.6M